Truist raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $709 from $640 and keeps a Buy rating on the shares. The firm’s survey work reinforces its belief in the sizable MASH patient numbers eligible for treatment that will translate to significant Rezdiffra revenues for Madrigal, the analyst tells investors in a research note, adding that Truist is increasing the US peak MASH patients treated with Rezdiffra estimates to 193K from 158K prior.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
- Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
- Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
- Madrigal Earnings Call: Rezdiffra Boom, Profits Delayed
- Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street